Lupin gets FDA approval for generic Femhrt tablets

Lupin_356_4013_356Drug major Lupin has received US health regulator’s approval to market Fyavolv tablets, used to treat postmenopausal osteoporosis, in the American market. The company has received received the final approval from the United States Food and Drug Administration (FDA) to market Fyavolv tablets. The company’s product is the generic equivalent of Warner Chilcott’s Femhrt tablets, which are indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis. The Mumbai-based firm has launched eight products in the US this fiscal and received approvals for 19 from the FDA. Read More

Comment Here

Leave a Reply